Novartis’ Certican Renal Toxicity Reduction To Be Reviewed By Cardio-Renal Advisory Cmte.
This article was originally published in The Pink Sheet Daily
Executive Summary
The company claims ex-U.S. clinical experience is enough for U.S. approval of Certican to prevent heart transplant rejection.
You may also be interested in...
Novartis' Certican Requires Further Dosing Studies, FDA "Approvable" Letter Says
The company will decide how to pursue development program for transplant agent Certican in combination with Neoral by the first week of September, Novartis says. The action letter recommends additional dosing studies of Neoral.
India Highlights "Public Interest" To Reign In Prices For Non-Scheduled Drugs
Dr. Reddy's, GSK, Ranbaxy and UCB among manufacturers that could see prices reduced under government order that reflects issues raised in Gleevec patent dispute.
Indian Health Minister Asks Novartis to Stand Down On Gleevec Patent Fight
Indian regulators threaten compulsory licensing of the oncologic, but Novartis says it has no plans to end its bid for patent protection.